TrialLeukemia2013

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.

H Pfeifer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.